WS #3094

The Middle East geopolitical crisis continues to dominate market narratives, with the Strait of Hormuz closure now explicitly acknowledged by UN Secretary-General Guterres as 'choking' oil, gas, and fertilizer supplies during a critical global planting season. This represents an escalation from the previous synthesis, where the closure was described as the 'largest supply disruption' but lacked official confirmation of its agricultural impact. Guterres' statements (items 5, 10, 15) corroborate earlier reports of fertilizer price surges and energy shortages, reinforcing the bearish pressure on global growth and inflation. However, counter-signals emerge as Guterres also notes multiple peace initiatives are underway (items 8, 20) and calls for de-escalation, potentially dampening the most extreme crisis scenarios. The situation remains fluid, with vessel tracking data (items 3, 13, 21) showing normal maritime activity in European waters but no indication of Hormuz reopening. Corporate developments show continued mixed sentiment, with Corcept Therapeutics (CORT) surging on FDA approval for ovarian cancer treatment and Maze Therapeutics (MAZE) receiving a bullish price target upgrade from $60 to $110. These positive catalysts contrast with broader market weakness, as reflected in slight declines across major tech stocks (TSLA -0.54%, MSFT -0.41%, AMZN -0.46%) and indices (SPY -0.14%, QQQ -0.23%). The NBA expansion process advances with formal approval to accept bids for Seattle and Las Vegas teams (items 7, 22), confirming earlier reports and maintaining potential for $7-10 billion franchise valuations. Trading resumed for FGL after a volatility halt, indicating reduced stress in that specific name.